Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Sees Large Drop in Short Interest

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 19,000 shares, a decline of 5.9% from the November 30th total of 20,200 shares. Based on an average daily trading volume, of 19,600 shares, the short-interest ratio is presently 1.0 days. Currently, 0.6% of the shares of the company are sold short.

Cryo-Cell International Stock Performance

Shares of Cryo-Cell International stock traded up $0.01 during trading hours on Wednesday, reaching $7.41. The stock had a trading volume of 9,303 shares, compared to its average volume of 11,188. Cryo-Cell International has a twelve month low of $4.47 and a twelve month high of $9.50. The company has a market cap of $59.72 million, a P/E ratio of -6.99 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The firm had revenue of $8.07 million during the quarter.

Cryo-Cell International Announces Dividend

The company also recently announced a — dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.25 dividend. The ex-dividend date was Friday, November 15th. Cryo-Cell International’s payout ratio is -94.34%.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC boosted its position in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,860 shares of the company’s stock after acquiring an additional 16,203 shares during the quarter. Geode Capital Management LLC owned 0.49% of Cryo-Cell International worth $254,000 at the end of the most recent quarter. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.